<DOC>
	<DOCNO>NCT02632006</DOCNO>
	<brief_summary>Objectives : The purpose study evaluate safety efficacy PIK-PD-1 Cells treatment advance Hepatocellular Carcinoma . Methods : This study design novel therapy use PIK-PD-1 cell . 40 patient advance Hepatocellular Carcinoma enrol . They randomly divide dendritic cell-precision multiple antigen T cell ( DC-PMAT ) group PIK-PD-1 cell group . Both DC-PMAT treatment PIK-PD-1 cell treatment perform every 3 week total three period . The mail clinical indicator Progression-Free-Survival Overall Survival .</brief_summary>
	<brief_title>Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 ( PIK-PD-1 ) Cells Treatment Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>A total 40 patient may enrol period 1-2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Age 20~70 year old , male female ; 2 . Barcelona Clinic Liver Cancer ( BCLC ) C stage ; indication operation , local treatment ( Transcatheter Arterial Chemoembolization ( TACE ) , percutaneous icro wave coagulation therapy ( PMCT ) , percutaneous ethanol injection therapy ( PEIT ) ) radiation therapy ; unable unwilling receive sorafenib therapy ; 3.ChildPugh score ≤ 9 ; 4.Eastern Cooperative Oncology Group ( ECOG ) score ≤ 2 ; 5.Life expectancy＞3 month ; 6. white blood cell ( WBC ) &gt; 3 x 10*9/L , Neutrophils &gt; 1 x 10*9/L , lymphocyte &gt; 1 x 10*9/L , hemoglobin ≥8.5g/dl , Platelet ≥50×109/L , prothrombin time ( PT ) 3 second , Cr blood urea nitrogen ( BUN ) less 3 time normal level ; 7 . Adequate venous access , blood cell production without taboo ; 8 . Signed informed consent . 1 . Immunosuppressive therapy need autoimmune disease organ transplantation history； 2 . HIV/Syphilis infection ; 3 . Positive blood culture image evidence infection ; 4 . Other drug , gene therapy , biological , chemotherapy radiation therapy use within 1 month . 5 . The history allergic reaction cell therapy cytokine . 6 . PD1 antibody use , allergy due PD1 antibody drug . 7 . History interstitial lung disease . 8 . History esophagus varicosis rupture haemorrhage . 9 . Other serious disease : heart , lung , kidney , digestive , nervous , mental disorder , immune regulatory disease , metabolic disease , infectious disease , Etc . 10 . Pregnant , lactate woman , pregnancy plan follow 2 year . 11 . Without sign informed consent . 12 . Other researcher consider one unsuitable inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>PIK-PD-1 Cells</keyword>
	<keyword>dendritic cell-precision multiple antigen T cell</keyword>
	<keyword>advanced hepatocellular carcinoma</keyword>
</DOC>